2024.08.20
On August 20, 2024, TYK Medicines, Inc. successfully launched its IPO and listing on the Main Board of the Hong Kong Stock Exchange under stock code 2410.HK. The offering raised approximately HK$ 579 million.
Founded in 2017, TYK Medicines is a clinical-stage biopharmaceutical company committed to the discovery, acquisition, development and commercialization of differentiated targeted therapies to address unmet medical needs in cancer treatment. The company has built a pipeline with 11 drug candidates including Core Product TY-9591 and Key Products TY-302 and TY-2136b.
JunHe has provided legal support to the company since its inception and has advised TYK Medicines on equity structuring, employee incentive plans, private equity financing from angel to D rounds, as well as its public offering and listing. JunHe has also provided legal guidance on pipeline licensing, licensed transactions, intellectual property and data compliance, and contributed to the company’s completion of multiple financing rounds and this successful IPO.
JunHe’s team was led by partners CHEN, Yan, WANG, Yi and SHANG, Shiming (George). They received valuable support from partners ZHOU, Fang (internal control), ZHAO, Hao (Gerry) (patent), GU, Yu (data compliance), and SHEN, Cheng and ZHENG Yu (litigation and compliance matters).
